Tags

Type your tag names separated by a space and hit enter

Imatinib mesylate-induced pseudoporphyria in two children.
Pediatr Dermatol. 2014 Sep-Oct; 31(5):603-7.PD

Abstract

Imatinib mesylate was the first of several tyrosine kinase inhibitors approved for use in the treatment of a number of human cancers. Adverse cutaneous reactions to imatinib are common. Pseudoporphyria has been infrequently reported in adults undergoing imatinib therapy for chronic myeloid leukemia. We present two children with pseudoporphyria induced by imatinib therapy for hematologic malignancies. In view of the burgeoning use of imatinib in children, physicians should be aware that pseudoporphyria may develop as a consequence of imatinib therapy.

Authors+Show Affiliations

Department of Paediatric Dermatology, Starship Children's Health, Auckland, New Zealand.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

24920470

Citation

Mahon, Caroline, et al. "Imatinib Mesylate-induced Pseudoporphyria in Two Children." Pediatric Dermatology, vol. 31, no. 5, 2014, pp. 603-7.
Mahon C, Purvis D, Laughton S, et al. Imatinib mesylate-induced pseudoporphyria in two children. Pediatr Dermatol. 2014;31(5):603-7.
Mahon, C., Purvis, D., Laughton, S., Bradbeer, P., & Teague, L. (2014). Imatinib mesylate-induced pseudoporphyria in two children. Pediatric Dermatology, 31(5), 603-7. https://doi.org/10.1111/pde.12380
Mahon C, et al. Imatinib Mesylate-induced Pseudoporphyria in Two Children. Pediatr Dermatol. 2014 Sep-Oct;31(5):603-7. PubMed PMID: 24920470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Imatinib mesylate-induced pseudoporphyria in two children. AU - Mahon,Caroline, AU - Purvis,Diana, AU - Laughton,Stephen, AU - Bradbeer,Peter, AU - Teague,Lochie, Y1 - 2014/06/12/ PY - 2014/6/13/entrez PY - 2014/6/13/pubmed PY - 2015/5/15/medline SP - 603 EP - 7 JF - Pediatric dermatology JO - Pediatr Dermatol VL - 31 IS - 5 N2 - Imatinib mesylate was the first of several tyrosine kinase inhibitors approved for use in the treatment of a number of human cancers. Adverse cutaneous reactions to imatinib are common. Pseudoporphyria has been infrequently reported in adults undergoing imatinib therapy for chronic myeloid leukemia. We present two children with pseudoporphyria induced by imatinib therapy for hematologic malignancies. In view of the burgeoning use of imatinib in children, physicians should be aware that pseudoporphyria may develop as a consequence of imatinib therapy. SN - 1525-1470 UR - https://www.unboundmedicine.com/medline/citation/24920470/Imatinib_mesylate_induced_pseudoporphyria_in_two_children_ L2 - https://doi.org/10.1111/pde.12380 DB - PRIME DP - Unbound Medicine ER -